上海泽德曼

Zedman Pharma is a clinical-stage biotechnology company based in Shanghai, China, focused on the discovery and development of small molecule drugs targeting the Aryl Hydrocarbon Receptor (AhR). The company's lead program, ZDM1001, is a topical AhR agonist currently in Phase 2 clinical trials for atopic dermatitis and psoriasis, offering a non-steroidal treatment option for inflammatory skin diseases. Zedman is also advancing ZDM2001, an oral AhR modulator for the treatment of inflammatory bowel disease. By leveraging its deep expertise in AhR biology, the company aims to address significant unmet needs in immunology and dermatology. Zedman has secured significant venture capital funding from top-tier investors to support its pipeline expansion and clinical progression.